The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Thursday newspaper round-up: BAE Systems, Mark Carney, Japan...

Thu, 20th Dec 2012 06:51

The continued haggling with Saudi Arabia over the price of 48 Eurofighter Typhoon jets could hit full-year profits at BAE Systems. The British defence contractor said that negotiations with the Royal Saudi Air Force about the price of the aircraft may not be concluded before its results announcement in February. That could wipe 3p per share off underlying earnings, the company warned in a trading update yesterday. Analysts are forecasting earnings of about 40p per share, compared with 37p in 2011. [The Times]Incoming Bank of England governor Mark Carney will pocket an annual £250,000 housing allowance, taking his total pay package close to £1m a year when he takes the reins next summer, the central bank has revealed. Carney will receive the allowance as part of a generous package put together by the chancellor, George Osborne, to lure him from his current job in Ottawa as boss of the Canadian central bank. It was already known that Carney would be paid a salary of £480,000 and pension contributions worth £144,000. He will also receive free health and dental insurance and the use of a chauffeur-driven car.[The Guardian]The Bank of Japan has stepped up its monetary easing with a Y10tn ($118bn) increase in the size of its asset-purchasing programme, and signalled that it could move to adopt a higher inflation target, as requested by Shinzo Abe, the incoming prime minister. Mr Abe welcomed the BoJ's move, saying "what we called for during the Lower House election is being realised one by one." During the election campaign, he called for the BoJ to do more to combat persistent deflation by adopting "unlimited" easing and an inflation target of 2 per cent or more. [Financial Times]The Department of Justice has charged two former UBS traders with conspiracy to manipulate Libor, on the same day the Swiss banking giant agreed to pay £940m in fines to settle charges linked to the key global interest rate. Tom Alexander William Hayes, 33-year-old British former Tokyo-based trader, and Roger Darin, a Switzerland-based managing director responsible for the bank's Libor submissions, were both charged with conspiracy, the US Justice Department said. Hayes was also charged with wire fraud and a "price-fixing violation arising from his collusive activity with another bank to manipulate Libor". Mr Hayes' official naming followed his arrest last week by the Serious Fraud Office in connection with its own investigation into Libor-rigging. Two other men, both brokers in the City, were also arrested. [The Telegraph]America's two largest mortgage lenders could have lost more than $3bn (£1.85bn) as a result of banks' alleged manipulation of Libor. Fannie Mae and Freddie Mac, the giant US mortgage lenders, have been told they should consider suing banks amid allegations that several major financial institutions rigged key borrowing rates for several years. According to reports, the two lenders are likely to have lost several billions of dollars as a direct result of interest rates being artificially increased and decreased by banks. [The Telegraph]Next year will be "a make or break" year for Greece's future as a member of the eurozone, the country's finance minister has said, warning Europe's leaders that Athens still faces "the possible risk" of crashing out of the currency bloc. "We can make it next year if we can stick to the programme agreed with the EU and IMF," Yannis Stournaras said in an interview with the Financial Times. However, "the break would be if the political system finds the situation too difficult to handle", he added, referring to the danger of social unrest about austerity that could force the two left-of-centre parties to bring down the governing coalition. [Financial Times]GlaxoSmithKline has reached a $150m (£92m) preliminary settlement with US drug wholesalers who claimed the company improperly delayed entry to the market of generic alternatives to its nasal spray Flonase, according to court documents. The settlement was reached with, among others, AmerisourceBergen, Cardinal Health and McKesson Corp, who maintained that Glaxo had abused the citizen's petition process to maintain a market monopoly. [The Independent]The soap opera continued at Bumi yesterday after yet another board member was forced to resign from the conflict-riven Indonesian coal miner created by Nat Rothschild and the Bakrie family in November 2010. In a day of action, the Takeover Panel ruled that there was improper disclosure about the close relationship between two key shareholders - the Bakrie brothers and Rosan Roeslani - when the group was created by injecting the Bakries' Indonesian coal-mining assets into Mr Rothschild's listed cash shell. The Panel ruled yesterday that the two groups had acted "in concert" - and cut the voting power of their combined 57 per cent stake almost in half, to 29.9 per cent. [The Independent]BC
More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.